TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gene expression related to proliferation, apoptosis, and differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: NAFLD Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: yield and success of KHB and EUS-FNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of diagnostic agreement between pCLE with topical CV and histopathological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pCLE imaging failure with topical CV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Artery Calcium Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Failure Readmission
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: New York Heart Association (NYHA) Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects insulin independent and free from severe hypoglycemia with HbA1c ≤ 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hair Thinning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal Hairline Recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scalp Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair Appearance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eyberg Child Behavior Inventory - intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Childhood Inventory-4 ODD scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Symptom Inventory-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AL-034
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) of AL-034
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Motor Fugl-Meyer (AMFM) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Motor Ability Test (AMAT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional Supplement Palatability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nutritional Supplement Intake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of SARS-CoV-2 in sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute post-operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from referral
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AHI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Orthodontic Plaque Index (OPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Graft Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Posttraumatic stress symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxidative stress status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal cytology screening outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of subjects with anti-hepatitis B concentration ≥10 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Kappa agreement between MRI estimates and HVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth at or more than 34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Number of fatalities in road accidents
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of lipase enzyme elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with moderate and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Pulmonary veins reconnection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effusion control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologically confirmed infectious disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative Incidence of Severe aGVHD at Day +100 Post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma n-3 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: In Hospital Major Bleed
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitative changes of white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Who Discontinued Before 6 Months of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Pain Scores Following Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Lower Lip Numbness Following Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Serum Lidocaine Concentration at 15 Minutes Post Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change of Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety test questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medical Outcomes Study Questionnaire Short Form 36 Health Survey score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient health questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chinese perceived stress scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the Curve (AUC) for insulin aspart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biodistribution of [18F]FTC-146
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Women's Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Female Sexual Function Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Menopause Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activities Specific Balance Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timed-Up-and-Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalization for the appearance of major vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Ipsilateral shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Enrolled Women Participating in All Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Women Indicating Somewhat or Very Satisfied on a 5-point Likert Scale Measure of Intervention Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Knee Outcome Survey-Activity of Daily Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain Medication Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perceived comfort reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Molecular diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Solicited Local Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Solicited General Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Seroconvert to HPV 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Seroconvert to HPV 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Seroconvert to HPV 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Seroconvert to HPV 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to asthma controller therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pain Relief From 0 to 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional activity of CYP3A4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients remaining in low disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child welfare status (recidivism or re-injury rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in natural killer cell cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody response to Tetanus toxoid vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody response to Pneumovax II vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Polypoid Mucosal Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Autism Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Alcohol Use Measured by Self Report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Use Measured by the Alcohol Biomarker, Phosphatidylethanol (PEth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cathelicidin levels in granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cytokine levels from stimulated Peripheral Blood Mononuclear Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum cytokines and acute phase proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in markers of response to tetanus vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum 25OH Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Without Prostate-specific Antigen Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volume decrease in relation to pressure application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Analogic Scale (VAS) for Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: changes in mean AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in UA resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reference range for thromboelastometry tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with migraine and non-migraine headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma HIV-1 RNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak aerobic capacity (relative VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunnstrom test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Pharmacokinetics of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in B cell functional responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in B cell phenotypic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sustained virological response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average Volume of Allogenic RBC Transfused Intra-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thickness of the abdominal wall muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female Sexual Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pressure in the Caudal Epidural Space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Peg-IFN-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients That Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Whole Blood NAD+ Level Change Over Baseline After Supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole Blood NADP+ Level Change Over Baseline After Supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole Blood NAD+ Plus NADP+ Level Change Over Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of all-type cancer
Endpoint domain: Mortality/survival
Primary endpoint: Disease-specific patient-reported outcome measure for pediatric celiac disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean over 3 days of Food quantities and macronutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean over 3 days of Intakes of Linoleic-, alpha linolenic-acids, DHA, ARA, minerals, Vitamins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin A intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) and Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sugar metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of contrast-induced nephropathy (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of medical visitation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Activity and expression of P-glycoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean percentage change in serum c-telopeptide (sCTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of symptom free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Day of recovery after sick leave
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite preparation, dispensing, and administration time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete blood count measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With an Objective Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induced Peanut Desensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduced wait time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With at Least One Skeletal-related Event (SRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prolonged abstinence from tobacco smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants in the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the concentration-time curve from time 0 to 25 hours (AUC(0-25))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Cumulative Lower Respiratory Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Liver fat content percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pedicle screw accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Minimum Lumen Diameter (MLD) at the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final opening or closure of macular hole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who died from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients able to consume >1000 mg of peanut proteins symptom-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Control of Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of child and family health functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of accruing patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to progression and survival time
Endpoint domain: Mortality/survival
Primary endpoint: Lesion-specific image-based FFRAngio calculation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time from randomization to all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Quick Inventory of Depressive Symptomatology Self reported (QIDS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hamilton Anxiety Rating Scale-A (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of fasting glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comparison score of flavor and aftertaste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence rate of acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Early liver function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum level of Non-Conventional T Lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Color analysis mixing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital-free days to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Oswestry Disability Index (ODI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dental fluorosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in SF-12 Health Survey Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 13CO2 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intact survival at NICU discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Cumulative Number of Gd Enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient response to QualPro intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of dimethyl fumarate use prescribed on-label versus off-label
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Successfully Switched
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with major/complete histologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV disclosure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status